Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies
Yuyao Liu1, Yuanqiang Wu1, Fang Wu1
1Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Abstract:
There is no standard therapy for nonsmall-cell lung cancer harboring rare coexistent EGFR mutations. Here, we report a female patient who was diagnosed as lung adenocarcinoma with three mutations of G724S, E709K, and V689I in exon 18. The patient responded to, but also showed rapid development of resistance to multiple therapies, including a second-generation EGFR-TKI of afatinib, a platinum-based doublet chemotherapy, and a multiple target TKI of anlotinib. As such, she ended up with a short overall survival time. Further research is required to understand the resistance mechanism(s) of these complex gene mutations.
Insights
No standard therapy exists for rare coexistent EGFR mutations in nonsmall-cell lung cancer. A patient with three exon 18 mutations showed rapid resistance to multiple treatments, resulting in poor survival.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Nonsmall-cell lung cancer (NSCLC) treatment is challenging when rare coexistent mutations are present.
- Epidermal growth factor receptor (EGFR) mutations are common drivers in NSCLC, but complex mutations lack standard therapeutic strategies.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle